To include your compound in the COVID-19 Resource Center, submit it here.

SB061: Phase I/II started

Symic and Nordic Bioscience began the double-blind, placebo-controlled, Estonian Phase I/II MODIFY-OA

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE